Thermo Fisher’s Strong Q4 Performance and Strategic Positioning Justify Buy Rating

CMB International Securities analyst Jill Wu has maintained their bullish stance on TMO stock, giving a Buy rating on February 3.

Jill Wu has given her Buy rating due to a combination of factors. Thermo Fisher’s impressive performance in the fourth quarter of 2024, with notable increases in both revenue and adjusted earnings per share, exceeded market expectations. This positive trend is projected to continue, supported by management’s optimistic guidance for 2025, indicating steady revenue and earnings growth.
Moreover, the company is benefiting from robust demand driven by pharmaceutical innovations and a favorable funding environment in the biotech sector. Thermo Fisher’s strategic investments, particularly in capital expenditures, highlight its commitment to meeting increasing market demand. Additionally, a significant recovery in the Chinese market, bolstered by government stimulus measures, positions the company well for future growth. These factors collectively underpin Jill Wu’s confidence in Thermo Fisher’s long-term growth potential, justifying the Buy rating.

Wu covers the Healthcare sector, focusing on stocks such as Thermo Fisher, BeiGene, and Innovent Biologics. According to TipRanks, Wu has an average return of -5.3% and a 41.38% success rate on recommended stocks.

In another report released on February 3, Raymond James also maintained a Buy rating on the stock with a $667.00 price target.